

Diabetes & Obesity

RESEARCH REVIEW™

Making Education Easy

Issue 154 – 2022

In this issue:

- Socioeconomic status and risk factors for complications in diabetes
- Anthropometric and adiposity indicators, and type 2 diabetes risk
- Closed-loop control in very young children with type 1 diabetes
- Variations in vildagliptin open-access use for type 2 diabetes in Waikato
- Dietary protein intake from different sources and new-onset diabetes risk
- Nudging towards healthier purchases during online supermarket shopping
- Glycaemic control after COVID-19 vaccination in type 1 diabetes
- Impact of birthweight on subsequent phenotype of type 2 diabetes
- Real-world adjunctive SGLT-2 inhibitor use for type 1 diabetes
- Low-carbohydrate diet in type 2 diabetes


Abbreviations used in this issue

CV = cardiovascular
HbA_{1c} = glycosylated haemoglobin
SGLT = sodium glucose cotransporter

CLICK HERE

to read previous issues of
Diabetes & Obesity Research Review

Kindly Supported by



Welcome to issue 154 of Diabetes and Obesity Research Review.

NZ research is represented this month in two papers, beginning with an Auckland study attempting to identify why young patients with type 2 diabetes develop complications earlier than those with type 1 diabetes of comparable duration. Moving down the North Island, just a bit, to the Waikato, our colleagues there have researched inequities in initial use of vildagliptin in general practice for type 2 diabetes. Also very topical at the moment, there is an evaluation of blood glucose level instability in type 1 diabetics during the week following COVID-19 vaccination. We conclude this month's issue with a trial of the impact of a non-calorie-restricted low-carbohydrate diet on glycaemic control, body composition and CV disease risk factors in patients with type 2 diabetes.

We hope you enjoy this selected research, and we look forward to your comments and feedback.

Best regards,

Professor Jeremy Krebs

jeremykrebbs@researchreview.co.nz

Socioeconomic status and risk factors for complications in young people with type 1 or type 2 diabetes

Authors: Wijayaratna S et al.

Summary: The reasons young people with type 2 diabetes develop complications earlier than those with type 1 diabetes were explored in this cross-sectional study of 731 and 1350 individuals, aged <40 years, diagnosed with the respective diabetes types between 15 and 30 years of age, and referred to secondary diabetes services in Auckland. Compared with the type 1 diabetes group, greater proportions of the type 2 diabetes groups were of Māori or Pasifika descent (24% and 71% [$p < 0.001$]), and 78% were from the lowest four New Zealand Deprivation Index categories ($p < 0.001$). BMI, mean HbA_{1c} level, macroalbuminuria and CV disease risk all increased progressively across the deprivation categories ($p \leq 0.01$). Deprivation was the strongest risk factor for poorly controlled diabetes (adjusted odds ratio 1.17 [95% CI 1.13, 1.22]), and each decile increase in the deprivation index was associated with an increased likelihood of increased urinary albumin-to-creatinine ratio (1.11 [1.06, 1.16]), and a 4% increase in CV disease risk irrespective of diabetes type.

Comment: Anyone working in diabetes will have observed the increase in rates of younger people with type 2 diabetes. Furthermore, they often have worse progression and rate of complications than older people developing type 2 diabetes or similar aged people with type 1 diabetes. This study reports an analysis of factors that might determine this from a cohort of patients referred to secondary care in the Auckland region. These data confirm the clinical observation and highlight how deprivation is an important factor in determining this increased risk. This shows how important the social determinants of health are, and critically how difficult it is to address the outcomes for these people from within the health sector alone. One caution on interpreting these data is the pattern of referral to secondary care, where as a rule all patients with type 1 diabetes are seen in secondary care, but increasingly only those with type 2 diabetes who have worse control or existing complications are referred, which would skew these findings. It would be interesting to repeat these analyses using the whole population data – if we had a national diabetes register. Wouldn't that be powerful!

Reference: *BMJ Open Diabetes Res Care* 2021;9:e002485

[Abstract](#)

New Year's resolutions and weight loss

Many of us make New Year's resolutions, and weight loss is a common goal.

[CLICK HERE](#) to read a timely review on the Role of Pharmacotherapy in Food Cravings.



Food craving is an important piece of the weight-loss puzzle. This article describes the issue of food cravings in patients with obesity, and the role that pharmacotherapy can play in the management of this issue.



trulicity
dulaglutide once-weekly injection

NEW

**New Zealand's only funded
GLP-1 RA is now available for
adults with type 2 diabetes.*1-3**

*Special Authority Criteria Apply.²

**PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING.
FULL DATA SHEET CAN BE ACCESSED AT WWW.MEDSAFE.GOV.NZ
OR ON REQUEST BY CALLING 0800 500 056.**

TRULICITY® (dulaglutide 1.5mg/0.5mL solution for injection, pre-filled pen [autoinjector]). **PRESCRIPTION MEDICINE. TRULICITY is funded under the New Zealand Pharmaceutical Schedule from 1 September 2021. Special Authority Criteria apply. INDICATIONS** – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. **CONTRAINDICATIONS** – Hypersensitivity to dulaglutide or any of the excipients. **PRECAUTIONS** – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience; Use in Pregnancy Category B3. **ADVERSE EFFECTS Clinical Trials Experience** – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity, atrial fibrillation. **DOSAGE AND ADMINISTRATION** – **Dosage:** Adults (≥18 years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients (≥65 years): dose adjustment not required. Children and adolescents (<18 years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. **Administration:** subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed. Please review full Data Sheet before prescribing. Full Data Sheet is available on request from Eli Lilly. Eli Lilly and Company (NZ) Limited, PO Box 109 197, Newmarket, Auckland 1149. Phone 0800 500 056. Based on Data Sheet approved 12 August 2021.

Abbreviation: GLP-1 RA, Glucagon-like peptide-1 receptor agonist.

References: 1. Trulicity Data Sheet August 2021. 2. Pharmaceutical Schedule. Available at: <https://schedule.pharmac.govt.nz/ScheduleOnline.php>. Last Accessed September 2021. 3. Trulicity Product Detail. Medsafe. Available at: <https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=21737>. Last accessed September 2021.

Trulicity® is a registered trademark of Eli Lilly and Company (NZ) Limited, PO Box 109 197 Newmarket, Auckland 1149, New Zealand. NZBN 9429039560643. Telephone 0800 500 056. PP-DG-NZ-0039. TAPS BG1593. ELI4479 Date of preparation: September 2021.

Lilly

Anthropometric and adiposity indicators and risk of type 2 diabetes

Authors: Jayedi A et al.

Summary: This systematic review with dose-response meta-analysis included 216 cohort studies (2.3 million individuals with type 2 diabetes among 26 million participants) reporting on the relationship between adiposity/bodyfat and type 2 diabetes risk in the general adult population. The risk of developing type 2 diabetes was found to increase significantly for each 5 kg/m² increase in BMI (relative risk 1.72 [95% CI 1.65, 1.81]), each 10cm increase in waist circumference (1.61 [1.52, 1.70]), each 0.1-unit increase in waist-to-hip ratio (1.63 [1.50, 1.78]), each 0.1-unit increase in waist-to-height ratio (1.73 [1.51, 1.98]), each unit increase in visceral adiposity index (1.42 [1.27, 1.58]), each 10% increase in bodyfat (2.05 [1.41, 2.98]), each 0.005-unit increase in body shape index (1.09 [1.05, 1.13]) and each 10% increase in body adiposity index (2.55 [1.59, 4.10]). There was a strong positive linear association identified between BMI and type 2 diabetes risk, with positive linear or monotonic associations detected in all regions and ethnicities with no marked deviation from linearity at any specific cutoff value. Indices of central fatness were also positively, linearly or monotonically associated with type 2 diabetes risk independently of overall adiposity; total and visceral fat mass were also positively, linearly or monotonically associated in a small number of studies.

Comment: Overweight and obesity are recognised and important modifiable risk factors for type 2 diabetes and CV disease. However, there are often debates about the relative utility of different measurements or estimates of body fatness, and cutoffs for each measurement. This systematic review and meta-analysis is particularly useful, because it includes a very large number of people, from very diverse populations. Whilst it confirms BMI as a very useful tool to predict risk of type 2 diabetes, what interested me was that the relationship appears more linear than what previous data have suggested as being a more exponential relationship. It also shows again that waist circumference adds additional information and nuance to the description of risk of body fatness. However, again I was interested to see that using a waist-to-height ratio may be better than waist alone or waist-to-hip ratio, which has traditionally been preferred. Despite this knowledge, waist circumference is still very poorly collected in clinical practice.

Reference: *BMJ* 2022;376:e067516

[Abstract](#)

Randomized trial of closed-loop control in very young children with type 1 diabetes

Authors: Ware J et al., for the KidsAP Consortium

Summary: Seventy-four children aged 1–7 years on insulin-pump therapy for type 1 diabetes received 16 weeks each of a closed-loop system and a sensor-augmented pump as control therapy in randomised order in this crossover trial. Compared with the control therapy, the closed-loop system was associated with a longer time with glucose levels in the target range (70–180 mg/dL; primary endpoint, mean adjusted difference, 8.7 percentage points [p<0.001]), a shorter time in a hyperglycaemic state (–8.5 percentage points [p<0.001]), a lower HbA_{1c} level (–0.4 percentage points [p<0.001]), and a lower mean sensor glucose level (–12.3 mg/dL [p<0.001]); time spent in a hypoglycaemic state did not differ significantly (p=0.74). During the closed-loop treatment, the median time spent in the closed-loop mode was 95%, and there was one case of severe hypoglycaemia.

Comment: The last decade has seen major advances in technology for insulin delivery and glucose sensing, but perhaps even more importantly, in algorithms for integrating the two. We are now seeing studies like this one coming through showing the benefits of this technology in achieving tight glycaemic control without risk of hypoglycaemia. Although the point of this study was to compare a closed-loop with sensor augmented pump therapy, to me the main take-home point for us in NZ is that this technology is now clearly superior to multiple daily injections. Furthermore, in this age-group where the burden of diabetes management for both the children and their parents is so high, safe and effective technology should now be the standard of care. It is great that pumps are funded in NZ, but woeful that we still have special authority criteria and more so that sensor technology is not available to those who can't afford it. It really is time that this is resolved.

Reference: *N Engl J Med* 2022;386:209–19

[Abstract](#)



Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

For your patients with type 2 diabetes†

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{1,2}

Click below to download your JARDIANCE resources

PRESCRIBING GUIDE **PATIENT BOOKLET**

Variation in open access vildagliptin use in Waikato patients with type 2 diabetes

Authors: Chepulis L et al.

Summary: This NZ research evaluated variations in initial vildagliptin use among adults with type 2 diabetes after the agent was approved for open access funding in October 2018. Among 3971 patients included in the analysis, 724 (18.2%) had initiated vildagliptin therapy, with a mean time to first dispensing of 192.1 days. Compared with patients of European ethnicity, those of Asian ethnicity were more likely to receive vildagliptin whereas Māori were less likely. Initiation of vildagliptin was also more likely in younger patients and those with an HbA_{1c} level of >64 mmol/mol. Across general practices, vildagliptin use ranged from 0.0% to 82.4%.

Comment: Type 2 diabetes is largely managed in primary care in NZ. In the last 3 years we have seen the availability of three new classes of medications for glucose level lowering, which have unique mechanisms of action and a diverse range of side effects. As with any new medication, it takes time for practitioners to become comfortable with prescribing them. This paper highlights some of the issues with one of these classes, the DPP (dipeptidyl peptidase)-4 inhibitors, and here vildagliptin, once it was available for unrestricted funded prescription. Compared with the SGLT-2 inhibitors and GLP (glucagon-like peptide)-1 agonists, vildagliptin is a very simple medication to use and has very few side effects to consider. Therefore it is surprising that the uptake wasn't greater. The authors highlight well reported inequities in prescription, and also enormous range between general practices. It will be interesting to see whether a similar pattern is seen with the SGLT-2 inhibitors and GLP-1 agonists. It suggests that a systematic way of educating practitioners, and proactively pro-equity approaches to introducing new medicines needs to be taken. Perhaps the new health system will enable this.

Reference: *N Z Med J* 2022;135(1548):77–88
Abstract

*38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).⁸²
*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. †In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. *The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med*. 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy:* When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy:* With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m² or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (NZ) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000402

Boehringer Ingelheim
Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461

Lilly

Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
NZBN 9429039560643

RACP MyCPD Program participants
can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.
Please CLICK HERE to download CPD Information



09-12 JUNE 2022
ENERGY EVENTS CENTRE
ROTORUA

gpcme.co.nz



Variety and quantity of dietary protein intake from different sources and risk of new-onset diabetes

Authors: Zhou C et al.

Summary: Associations of protein intake variety and quantity with new-onset diabetes were explored using Chinese health and nutrition survey data from 16,260 individuals free of diabetes at baseline. Over a median 9.0 years of follow-up, 1100 individuals developed diabetes. U-shaped associations were identified for total, whole grain-derived and poultry-derived protein with new-onset diabetes, J-shaped associations were seen between unprocessed or processed red meat-derived protein and new-onset diabetes, a reverse J-shaped association was evident between fish-derived protein and new-onset diabetes, L-shaped associations were detected between egg-derived and legume-derived protein with new-onset diabetes, and a reverse L-shaped association was apparent between refined grain-derived protein and new-onset diabetes (all $p < 0.001$ for nonlinearity). Each incremental increase in a high variety score for protein source was associated with a decreased risk of new-onset diabetes (hazard ratio 0.69 [95% CI 0.65, 0.72]).

Comment: This is a really interesting perspective on the relationship between dietary protein and risk of type 2 diabetes. Historically there has been a lot of focus on macronutrient composition, as percentages of total energy intake. There has also been a plethora of studies looking at type of fat and type of carbohydrate, but relatively few studies on protein, particularly on the sources of protein. This study demonstrates how important that is, with much lower rates of new-onset diabetes where dietary protein is derived more from plant sources or fish than from red meat. These data add further weight to the changing focus from macronutrient proportions to macronutrient quality/composition. It is very likely that these differences are at least in part mediated by other components of the foods, and/or the interactions between them.

Reference: *BMC Med* 2022;20:6

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).



Nudging customers towards healthier food and beverage purchases in a real-life online supermarket

Authors: Stuber JM et al.

Summary: Customers purchasing food via an online supermarket over a 1-month period ($n=11,775$) were randomised to a control condition, information nudges, position nudges or both information and position nudges. Sales data revealed no overall significant effects between the groups, although effects were modified by area-level deprivation with shoppers from deprived areas allocated to information nudges purchasing a higher percentage of healthy products of 2.4% relative to controls; no significant difference was seen for position or combined nudges. In contrast, shoppers from nondeprived areas purchased lower percentages of healthy products when exposed to information nudges and combined nudges (-1.6% and -2.1% , respectively), but not position nudges.

Comment: Changing dietary pattern is very difficult, and multiple strategies are likely required to achieve sustained change that is big enough to make an impact on health. This paper reports an interesting approach, which has been possible because of an increasing trend in online grocery shopping. Supermarkets have used product placement as a tool to influence purchasing for a long time. Cynically this is usually to increase profits rather than improve health, but the effectiveness of this tool is well known. This paper reports using information or positional 'nudges' to try to move purchases to a more healthy profile. With the methods used here, only information nudges in more deprived population groups made any significant improvement. Given that we have seen the importance of deprivation in risk for diabetes and outcomes, this is still useful. There may also be scope for different types or styles of 'nudging' that can be tested as well.

Reference: *BMC Med* 2022;20:10

[Abstract](#)

The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes

Authors: Heald AH et al.

Summary: Temporary instability of blood glucose levels following vaccination against SARS-COV-2 was explored in this analysis of interstitial glucose levels from 97 consecutive adults with type 1 diabetes using the FreeStyle Libre® flash glucose monitor. Compared with prevaccination values, the mean percentage of interstitial glucose levels in the target range of 3.9–10.0 mmol/L was significantly lower during the 7 days after vaccination (52.2% vs. 55.0% [$p=0.030$]), with 58% of participants experiencing a reduction in the time in target range in the week after vaccination, 30% having a decrease of $>10\%$ and 10% having a decrease $>20\%$. The effect of vaccination on interstitial glucose level targets during the subsequent week was most pronounced for metformin/dapagliflozin plus basal bolus insulin recipients and for participants with an HbA_{1c} level below the median value (respective changes, -7.6% and -5.7%).

Comment: Anecdotally, people with diabetes have reported a rise in their blood glucose levels in the week after they have had their COVID vaccination, and therefore this study caught my eye. In people with type 1 diabetes who were using flash glucose monitoring, time in range during the week before the vaccine was compared with the week after the vaccine. About a third of people had a deterioration in time in range, but curiously some also had better control. This analysis doesn't take into consideration any changes in insulin dosing and attention to corrections, etc. What I found interesting was that in this UK-based study, almost a third of patients with type 1 diabetes were using either metformin or an SGLT-2 inhibitor in addition to their insulin. This is much higher than I expect will be the case in NZ, even acknowledging the funding issues for SGLT-2 inhibitors. These individuals were more likely to have worse control after the vaccine.

Reference: *Diabet Med* 2021:e14774

[Abstract](#)

RAMADAN
STARTS 1 APRIL

Diabetes and Ramadan

Practical guidelines: pre-Ramadan assessment, medication adjustment during Ramadan and a post-Ramadan follow-up.

Research Review E-Learning Module

This module is based on the podcast by Sydney Endocrinologist and Clinical Lecturer, Dr Marwan Obaid, who provides overview of the importance of Ramadan to Muslims and practical guidance. The module is endorsed by the RNZCGP for up to 1 CME credit and by The College of Nurses for 1 hour professional development.

This E-Learning Module will give you an improved understanding of how to:

- Provide advice regarding fluids and dietary intake during Ramadan
- Provide advice regarding physical activity during Ramadan
- Provide advice regarding blood glucose monitoring during Ramadan
- Adjust diabetes medications
- Advise patients of risk factors which indicate they must break their fast

CLICK HERE to
VIEW THE PODCAST

GPs:
START MODULE

NURSES:
START MODULE



The impact of birthweight on subsequent phenotype of type 2 diabetes in later life

Authors: Paulina C et al.

Summary: The impact birthweight has on phenotype at diagnosis of type 2 diabetes and subsequent glycaemic deterioration was explored in this analysis of 48,000 births in Scotland. Each 1kg increment in lower birthweight was associated with a 293-day younger age at type 2 diabetes diagnosis ($p=0.005$) and a 1.29 kg/m^2 lower BMI at diagnosis ($p<0.001$); there was no significant association of birthweight with diabetes progression.

Comment: As the authors say, it is well known that low birthweight is associated with later lifetime risk of developing type 2 diabetes. There are many potential reasons why that might be, including the effect of intrauterine stress influencing β -cells or gene programming related to downstream insulin-mediated glucose uptake and utilisation. This interesting study shows that individuals with low birthweight were more likely to develop type 2 diabetes at a younger age and at a lower BMI than their normal birthweight counterparts. Without conducting detailed clamp studies of β -cell function and insulin sensitivity, these data suggest the effect is more likely mediated by reduced β -cell function and/or mass rather than insulin resistance. This is the opposite of what I might have predicted, and sadly not something that is likely modifiable.

Reference: *Diabet Med* 2022:e14792

[Abstract](#)

Real-world evidence of efficacy and safety of sodium–glucose cotransporter 2 inhibitors as adjunctive therapy in adults with type 1 diabetes

Authors: Palanca A et al.

Summary: Real-world efficacy and safety of SGLT-2 inhibitors combined with insulin for the treatment of type 1 diabetes were reported for 199 adults from two European centres. After 12 months of this treatment, significant reductions were seen for mean HbA_{1c} level (-0.5 percentage points), bodyweight (-2.9kg) and daily insulin use (-8.5%), with the greatest reduction in HbA_{1c} level seen in patients with a baseline HbA_{1c} level of $>64 \text{ mmol/mol}$ (8.0% ; reduction of -0.7 percentage points) and the greatest weight loss seen in those with a BMI $>27 \text{ kg/m}^2$ (-3.5kg reduction). Patients with an estimated glomerular filtration rate $<90 \text{ mL/min/1.73m}^2$ at baseline experienced an increase in this parameter of $4.5 \text{ mL/min/1.73m}^2$, whereas those with a urinary albumin-to-creatinine ratio $>15 \text{ mg/g}$ experienced a decrease in this parameter of -16.6 mg/g . The overall incidence of adverse events was 28.6% , including genital infections (22.6%), ketosis (2.5%) and diabetic ketoacidosis (3.5%); there were no cases of severe hypoglycaemia.

Comment: The use of SGLT-2 inhibitors in type 1 diabetes is very controversial, mainly because of the risk of ketoacidosis. I have had a small number of people with type 1 diabetes using them with mixed experience, but a generally impressive reduction in glucose level variability. This study reports data from real-world experience of their use in 200 people with type 1 diabetes. The observations confirm my experience of reductions in HbA_{1c} level, weight and insulin doses. However, there were a small number of episodes of ketoacidosis, but only 3.5% , which is much lower than many might have expected. Overall, I think these data are more reassuring than I would have expected, and suggest that there may be a place for these agents in type 1 diabetes after all. We must be cautious and extremely careful in who we select, how we educate and ensure safety, but watch this space.

Reference: *Diabetes Care* 2022:dc211584

[Abstract](#)

Independent commentary by
Professor Jeremy Krebs MBChB, FRACP, MD



Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He is a Professor with the University of Otago, and former Director of the Clinical Research Diploma at Victoria University - which he established. **FOR FULL BIO** [CLICK HERE](#).

Effects of a 6-month, low-carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes

Authors: Gram-Kampmann EM et al.

Summary: Patients with type 2 diabetes were randomised to a 6-month calorie-nonrestricted low-carbohydrate diet (maximum 20% total energy intake from carbohydrates; $n=49$) or a control diet (50–60% of total energy from carbohydrates; $n=22$) in this open-label trial. Compared with the control diet, the low-carbohydrate diet was associated with a 30.5% reduction in energy from carbohydrate and a 30.6% increase in energy from fat, as well as reductions in HbA_{1c} level at 3 months of 8.9 mmol/mol , which was maintained out to 6 months (-7.5 mmol/mol), bodyweight of 3.9kg , BMI of 1.4 kg/m^2 and waist circumference of 4.9cm (all $p<0.01$), which were accompanied by reductions in total fat mass of 2.2kg ($p=0.027$) and lean mass of 1.3kg ($p=0.017$). There were no significant changes in blood lipid levels or blood pressure after 6 months, physical activity levels were maintained, and no episodes of severe hypoglycaemia were reported.

Comment: There continues to be interest in low or very low carbohydrate diets as a way to help people with type 2 diabetes better manage their condition. There is perhaps no other diet/nutrition controversy that creates more passionate debate! Despite the interest and range of opinion, there remain few well-conducted randomised controlled trials that have been conducted specifically in people with type 2 diabetes or prediabetes. This study does that, and shows significant benefits of a low-carbohydrate diet on glycaemic control, the primary endpoint, and weight, with no adverse effects on lipid levels, blood pressure or rates of hypoglycaemia. This is all very encouraging, but once again it was only a 6-month intervention. We still need a well-conducted study of this nature that extends out to at least 2 years before we can really make conclusions. However, these data are reassuring that low-carbohydrate diets are a valid short-term approach for people with type 2 diabetes.

Reference: *Diabetes Obes Metab*; Published online Jan 4, 2022

[Abstract](#)

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

goodfellow symposium 2022

March 26-27

Live online event